Clene to Showcase Neurodegenerative Disease Research at Jones Las Vegas Technology Conference

Clene Inc., a clinical-stage biopharmaceutical company specializing in neurodegenerative disease research, will present its innovative work at the upcoming Jones Las Vegas Technology and Innovation Conference on April 8-9, 2025. The event, to be held at The Venetian Resort in Las Vegas, Nevada, will provide a platform for direct engagement between company executives and institutional investors.

The conference, organized by JonesTrading with marketing support from B2i Digital, Inc., will feature one-on-one meetings, fireside chats, and panel discussions. These interactive sessions will allow Clene's leadership, including CEO Rob Etherington, to share insights into their cutting-edge research focused on improving mitochondrial health and protecting neuronal function in diseases such as amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis.

Notable keynote speakers will include Dr. Charity Dean, CEO of PHC Global, and Eric F. Trump, Executive Vice President of The Trump Organization, adding further prestige to the event. The conference will also host a Golf Event and Cocktail Reception, providing additional networking opportunities for participants.

For Clene, this conference represents a critical opportunity to showcase their investigational therapy CNM-Au8®, which targets mitochondrial function and the NAD pathway while reducing oxidative stress. By participating in this conference, the company aims to attract potential investors and raise awareness about their innovative approach to treating neurodegenerative diseases.